Rapamycin, a potent immunomodulatory drug, has shown promise in the amelioration of
numerous age-associated diseases including cancer, Alzheimer's disease and cardiac …

The FDA approved drug rapamycin increases lifespan in rodents and delays age-related
dysfunction in rodents and humans. Nevertheless, important questions remain regarding the …

Cellular senescence is an age‐associated phenomenon that promotes tumor invasiveness
owing to the secretion of proinflammatory cytokines, proteases, and growth factors. Herein …

Interventions that target biological mechanisms of aging have great potential to enhance
quality of life by delaying morbidity and mortality. The FDA-approved drug rapamycin is a …

Inhibition of the mechanistic target of rapamycin (mTOR) pathway by rapamycin (RAPA), an
FDA-approved immunosuppressive drug used as a clinical therapy to prevent solid organ …

The drug rapamycin is the only pharmacological agent thus far shown to reproducibly
extend lifespan and delay a subset of age-associated pathologies in multiple strains of mice …

Background Aging is associated with increased inflammation and risk of community-
acquired pneumonia. Streptococcus pneumoniae co-opts the nuclear factor κ B (NFkB) …

In 2009, rapamycin was reported to increase the lifespan of mice when implemented later in
life. This observation resulted in a sea-change in how researchers viewed aging. This was …

Alveolar macrophages (AMs) are the first immune cells to respond to an invading pathogen
and coordinate the inflammatory response within the lungs. Studies suggest that …

Aging can not only shorten a healthy lifespan, but can also lead to multi-organ dysfunction
and failure. Anti-aging is a complex and worldwide conundrum for eliminating the various …